Silicon Valley startup InSilixa roped in $13M in financing to develop its innovative molecular diagnostic tests for drug-resistant bacteria and infections.
Here's why: The top 5 diagnostics-related venture capital deals in the 2014 second quarter are much more robust than those from the previous quarter, reflecting a larger med tech trend that produced a healthy hike in both deal value and volume versus Q1.
A year ago, Myriad Genetics launched its MyRisk Hereditary Cancer multi-gene molecular diagnostic test with great fanfare. Now, the Utah-based company is touting some eye-popping clinical trial results in a bid to reinforce its utility in the marketplace.
POPULAR COMMENT THREADS
As concern mounts over the deadly Ebola epidemic, French scientists are developing a diagnostic tool that works similar to a home pregnancy test and can quickly identify the virus through a tiny fluid sample. Read more >>
QuantuMDx is teaming up with a Swiss nonprofit organization to develop its handheld test for tuberculosis, building momentum for a full commercial rollout of its innovative diagnostic tool.
Molecular diagnostics developer Nanosphere reeled in $18.4 million in a stock sale with the proceeds slotted to be used for general corporate purposes and working capital.
Researchers at the University of Wisconsin-Madison have come up with an implantable sensor so thin that scientists studying the brain can see through it using a wide range of imaging technologies.
BioFire, a subsidiary of French diagnostics outfit bioMérieux, was granted emergency authorization from the FDA for two of its Ebola tests.
Amid the rise of antibiotic-resistant superbugs in hospital systems and facilities, scientists at Johns Hopkins are developing a real-time tracking system that could quickly diagnose and monitor antibiotic-resistant bacterial infections.
From Our Sister Sites
A panel of FDA advisers voted in favor of approving Daiichi Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company's odds of finally launching the drug in the U.S.
In this week's EuroBiotech Report, a who's who of Big Pharma companies joined a European public-private consortium to develop and test new economic models of antibiotic R&D with the goal of making antibiotic R&D economically attractive again. And more.